| Literature DB >> 34510703 |
Sirichai Wiriyatanakorn1, Anucha Mukdadilok2, Surasak Kantachuvesiri2, Chusana Mekhora3, Teerapat Yingchoncharoen1.
Abstract
Salt intake over reference level would result in elevated blood pressure (BP) and long-term morbidity. Salt meter is a device used to detect sodium content in daily food. This study aimed to evaluate the efficacy of salt-meter addition to dietary education. The authors conducted a randomized-controlled trial in hypertensive patients with uncontrolled BP (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg). Patients were randomized to receive salt meter plus dietary education (group A) or education only (group B), and followed up for 8 weeks. The primary endpoint was change in 24-h urinary sodium excretion. Changes in BP, salt taste sensitivity, cardio-ankle vascular index (CAVI) were also analyzed. There were total number of 90 patients who had complete follow-up, 45 in each group. Mean age was 62.9 years and 53% were females. Mean baseline 24-h urine sodium was 151.6 mmol/24 h and mean SBP and DBP were 152.8 and 83.4 mmHg, respectively. Baseline characteristics were similar between two groups. At 8 weeks, mean change in urine sodium were -31.83 mmol/24 h and 0.36 mmol/24 h in group A and group B, respectively (p = .006). Mean decrease in BP were SBP, 14.44 versus 8.22 mmHg (p = .030), and DBP 5.53 versus 1.93 mmHg (p = .032). The salt sensitivity was improved more in group A. There was no different between change in CAVI. From this study, salt meter in conjunction with dietary education, for self-monitoring of salt intake is superior to education alone in hypertensive patients, and provided better blood pressure control. Salt meter should be considered in uncontrolled hypertensive patients.Entities:
Keywords: hypertension; salt; salt meter; uncontrolled
Mesh:
Substances:
Year: 2021 PMID: 34510703 PMCID: PMC8678669 DOI: 10.1111/jch.14344
Source DB: PubMed Journal: J Clin Hypertens (Greenwich) ISSN: 1524-6175 Impact factor: 3.738
FIGURE 1Protocol flow chart
FIGURE 2(A) Salt meter devices used in this study (developed in collaboration with Faculty of Engineering, Mahidol University, Nakorn Pathom, Thailand). (B) Examples of display from salt meter, the measured concentration of sodium chloride (NaCl) content in the interested food showed as percentage and emoticon facial expression
Demographic data and baseline characteristics
| Baseline characteristics | Group A (salt meter) | Group B (Control) |
|
|---|---|---|---|
| Age, mean ± SD (years) | 63.2 ± 11.9 | 62.5 ± 10.0 | .754 |
| Female sex (%) | 26 (58) | 23 (51) | .672 |
| No. of antihypertensive drugs, mean | 1.9 | 1.7 | .420 |
| Types of antihypertensive drugs | |||
| Diuretics | 13.0 % | 17.4 % | .636 |
| ACEi or ARB | 82.6 % | 69.6 % | .300 |
| Calcium‐channel blocker | 56.5 % | 60.8 % | .765 |
| Beta‐blocker | 73.9 % | 52.2 % | .127 |
| Smoking (%) | 15.7 | 10.5 | .497 |
| Body weight, mean (kg) | 71.8 | 66.6 | .115 |
| Body mass index, mean ± SD (kg/m2) | 27.9 ± 5.3 | 26.3 ± 5.1 | .250 |
| Blood pressure, mean ± SD (mmHg) | |||
| Systolic | 153.9 ± 10.2 | 151.3 ± 12.1 | .308 |
| Diastolic | 83.8 ± 8.0 | 82.5 ± 9.8 | .513 |
| 24‐h urine sodium, mean ± SD (mmol) | 153.8 ± 61.7 | 144.2 ± 51.9 | .427 |
| Creatinine, mean ± SD (mg/dl) | 0.86 ± 0.2 | 0.87 ± 0.3 | .728 |
| eGFR, mean ± SD (ml/min/1.73 m2) | 84.1 ± 17.7 | 84.6 ± 21.2 | .903 |
| Serum sodium, mean ± SD (mEq/l) | 140.2 ± 2.2 | 139.1 ± 7.3 | .361 |
Abbreviations: ACEi, angiotensin‐converting enzyme inhibitors; ARB, angiotensin‐II receptor blockers; eGFR, estimated glomerular filtration rate.
Primary and secondary outcomes (mean ± SD)
| Group A (salt meter) | Group B (control) | ||||||
|---|---|---|---|---|---|---|---|
| Initial | Week 8 | Change | Initial | Week 8 | Change |
| |
|
| |||||||
| 24‐h urinary sodium excretion (mmol) | 153.8 ± 61.7 | 121.9 ± 59.3 | –31.8 ± 49.2 | 144.2 ± 51.9 | 144.6 ± 65.2 | 0.4 ± 59.4 | .006 |
|
| |||||||
| Blood pressure | |||||||
| Systolic blood pressure (mmHg) | 153.9 ± 10.2 | 139.5 ± 13.4 | –14.4 ± 14.2 | 151.5 ± 12.1 | 143.3 ± 16.0 | –8.2 ± 12.6 | .030 |
| Diastolic blood pressure (mmHg) | 83.8 ± 8.0 | 78.2 ± 7.5 | –5.5 ± 7.3 | 82.5 ± 9.8 | 80.5 ± 9.8 | –1.9 ± 8.1 | .032 |
| Salt taste sensitivity | |||||||
| Salt taste detection threshold | 7.57 ± 0.31 | 6.03 ± 0.31 | –1.27 ± 0.07 | 7.02 ± 0.39 | 6.75 ± 0.39 | –0.27 ± 0.79 | .243 |
| Salt taste recognition threshold | 13.65 ± 0.48 | 12.95 ± 0.34 | –0.70 ± 0.10 | 13.17 ± 0.39 | 11.58 ± 0.43 | –0.62 ± 0.10 | .928 |
| Cardio‐ankle vascular index (CAVI) | 8.08 ± 1.21 | 8.21 ± 1.55 | 0.02 ± 1.33 | 8.65 ± 0.99 | 8.43 ± 1.11 | –0.11 ± 0.83 | .738 |
FIGURE 3(A) 24‐h urine sodium excretion (mean ± SD) at initial, week‐4, and week‐8. (B) Mean change in 24‐h urine sodium excretion from baseline to week 8 in group. A (device) and group B (control)
FIGURE 4Mean change in systolic and diastolic blood pressure from baseline to week 8 in group A (device) and group B (control)